We are live on ! Find out more
NBRV

Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV

Delisted

NBRV was delisted on the 31st of July, 2023.

Back to rankings

41 hedge funds and large institutions have $173M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

360% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 5

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

78% more funds holding

Funds holding: 23 → 41 (+18)

7% less capital invested

Capital invested by funds: $187M → $173M (-$14M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
41
Holders Change
+18
Holders Change %
+78.26%
% of All Funds
1.02%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
23
Increased
11
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$11.9M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$6.56M
3
MWNA
Marshall Wace North America
New York
+$6.06M
4
LCM
Laurion Capital Management
New York
+$5.56M
5
BBA
Baker Bros. Advisors
New York
+$5.52M

Top Sellers

Rank Fund Capital Flow
1
OFM
Omega Fund Management
Massachusetts
-$11.9M
2
ACP
Acuta Capital Partners
California
-$5.12M
3
EC
EcoR1 Capital
California
-$2.77M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.76M
5
TCM
Tekla Capital Management
Massachusetts
-$1.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
MP
26
MSD Partners
New York
$410K +$469K +200 New
SSA
27
Schonfeld Strategic Advisors
New York
$410K +$469K +200 New
CSS
28
Cubist Systematic Strategies
Connecticut
$348K +$399K +170 New
Jane Street
29
Jane Street
New York
$293K +$335K +143 New
BCM
30
BlueCrest Capital Management
Jersey
$239K +$274K +117 New
Commonwealth Equity Services
31
Commonwealth Equity Services
Massachusetts
$219K +$131K +56 +110%
FO
32
FT Options
Illinois
$164K +$46.9K +20 +33%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$99K +$113K +48 New
QT
34
Quantbot Technologies
New York
$79K +$91.5K +39 New
Bank of Montreal
35
Bank of Montreal
Ontario, Canada
$49K +$56.3K +24 New
Bank of America
36
Bank of America
North Carolina
$13K – – –
UBS Group
37
UBS Group
Switzerland
$10K +$11.7K +5 New
RE
38
RBC Europe
United Kingdom
$8.19K +$9.38K +4 New
CHP
39
Cable Hill Partners
Oregon
$4K +$4.69K +2 New
NFG
40
Next Financial Group
Texas
$2K +$2.35K +1 New
TDC
41
Thompson Davis & Co
Virginia
$2K +$2.35K +1 New
Wells Fargo
42
Wells Fargo
California
$2K +$2.35K +1 New
OFM
43
Omega Fund Management
Massachusetts
– -$11.9M -4,556 Closed
AIP
44
Almanack Investment Partners
Pennsylvania
– -$1.63M -3,629 Closed
EC
45
EcoR1 Capital
California
– -$2.77M -1,059 Closed
TCM
46
Tekla Capital Management
Massachusetts
– -$1.68M -597 Closed
Millennium Management
47
Millennium Management
New York
– -$764K -292 Closed
1
2

NBRV Hedge Fund Activity: Q3 2017 in Review

41 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2017, worth a combined $173M — down 7.5% from $187M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new NBRV positions and 5 closed out — a net gain of 18 holders — while 11 added to existing stakes and 4 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $11.9M. The largest seller was Omega Fund Management, exiting entirely with an estimated $11.9M sold.

  • 41 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2017, up from 23 in Q2 2017.
  • Funds reported $173M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2017, down 7.5% quarter-over-quarter.
  • 23 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2017 and 5 closed out, a net change of +18 holders.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2017 was Morgan Stanley, an estimated $11.9M added.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q3 2017 was Omega Fund Management, an estimated $11.9M sold.

Based on aggregated 13F filings for Q3 2017.